Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of High-Dose AG0302-COVID19
NCT04993586Phase 2Completed
- Sponsor
- AnGes, Inc.
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AG0302 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by AnGes, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Immunogenicity at Week 13. Started Jul 2021; status: completed.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04993586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993586.